KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Goodwill (2016 - 2025)

Pfizer (PFE) has disclosed Goodwill for 16 consecutive years, with $69.1 billion as the latest value for Q3 2025.

  • On a quarterly basis, Goodwill rose 0.77% to $69.1 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $69.1 billion, a 0.77% increase, with the full-year FY2023 number at $67.8 billion, up 31.94% from a year prior.
  • Goodwill was $69.1 billion for Q3 2025 at Pfizer, up from $68.4 billion in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $69.1 billion in Q3 2025 to a low of $49.2 billion in Q4 2021.
  • A 5-year average of $59.5 billion and a median of $59.6 billion in 2023 define the central range for Goodwill.
  • Peak YoY movement for Goodwill: dropped 14.68% in 2021, then soared 31.94% in 2023.
  • Pfizer's Goodwill stood at $49.2 billion in 2021, then increased by 4.4% to $51.4 billion in 2022, then soared by 31.94% to $67.8 billion in 2023, then rose by 1.16% to $68.6 billion in 2024, then grew by 0.77% to $69.1 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Goodwill are $69.1 billion (Q3 2025), $68.4 billion (Q1 2025), and $68.6 billion (Q3 2024).